MNC在中美市场打响新一轮自建产能保卫战，留给CDMO的增量订单正在减少。图源：阿斯利康 Catalent正面回应收购事件，然大客户阿斯利康已加速离开 ...

Catalent plans to invest an estimated $45 million to expand its facilities and purchase new equipment for its production ...

Catalent Pharma Solutions' latest expansion in Madison is bringing a boost to Wisconsin’s growing biohealth sector, with a ...

Catalent's deal with Elliott now makes the hedge fund an indirect player in the story of Wegovy, the first-to-market in a new class of highly effective weight-loss drugs which some analysts ...

Catalent on Wednesday confirmed its Bloomington, Indiana, site was the facility in question, where the FDA made three observations during a pre-approval inspection.

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss ...

Catalent Inc's CTLT Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consensus of $939.14 million. Overall, organic net revenue decreased by 8% ...

Catalent’s Geographic Performance. Geographically, CTLT operates via three regions — the United States, Europe and Other. Revenues from the United States were $658 million (up 2% year over ...

Joe Ferraro joined Catalent in 2023, just before a blizzard of challenges hit. Courtesy photo Joe Ferraro doesn’t believe in micromanaging. Instead, he empowers his team, trusting them to rise ...

Catalent continues to manufacture Wegovy after all, which promises to be a highly lucrative contract going forward, given analysts believe it may drive revenues in excess of $25bn per annum.

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year.The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share.

Catalent has endured a series of operational and production-based hurdles over the last 2 periods. Read why I revised my rating on CTLT to Hold.